Exact Sciences Corporation $EXAS Shares Sold by Savant Capital LLC

Savant Capital LLC reduced its position in Exact Sciences Corporation (NASDAQ:EXAS) by 58.9% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 15,919 shares of the medical research company’s stock after selling 22,816 shares during the quarter. Savant Capital LLC’s holdings in Exact Sciences were worth $846,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Great Lakes Advisors LLC boosted its stake in shares of Exact Sciences by 3.7% in the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after purchasing an additional 178 shares during the period. Nissay Asset Management Corp Japan ADV increased its stake in Exact Sciences by 0.8% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company’s stock worth $971,000 after buying an additional 187 shares during the period. DekaBank Deutsche Girozentrale increased its stake in Exact Sciences by 0.4% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 58,333 shares of the medical research company’s stock worth $3,127,000 after buying an additional 217 shares during the period. IFP Advisors Inc lifted its holdings in Exact Sciences by 6.5% during the 2nd quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock worth $237,000 after buying an additional 273 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Exact Sciences by 37.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 1,018 shares of the medical research company’s stock valued at $54,000 after buying an additional 275 shares during the period. 88.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Exact Sciences

In related news, EVP Brian Baranick sold 2,858 shares of the business’s stock in a transaction that occurred on Tuesday, November 4th. The stock was sold at an average price of $70.08, for a total transaction of $200,288.64. Following the completion of the sale, the executive vice president owned 22,368 shares in the company, valued at $1,567,549.44. The trade was a 11.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James Edward Doyle sold 2,000 shares of the stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the transaction, the director owned 57,962 shares in the company, valued at $3,477,720. This represents a 3.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.20% of the stock is owned by insiders.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $67.75 on Friday. The company has a market cap of $12.84 billion, a P/E ratio of -12.48, a PEG ratio of 5.56 and a beta of 1.34. The firm has a fifty day moving average price of $59.57 and a 200 day moving average price of $54.03. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. Exact Sciences Corporation has a 12 month low of $38.81 and a 12 month high of $72.81.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.11. The company had revenue of $850.74 million during the quarter, compared to the consensus estimate of $810.42 million. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.Exact Sciences’s revenue for the quarter was up 20.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.21) EPS. Exact Sciences has set its FY 2025 guidance at EPS. Sell-side analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. UBS Group decreased their target price on Exact Sciences from $61.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, August 7th. TD Cowen boosted their target price on Exact Sciences from $74.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Guggenheim upped their price target on Exact Sciences from $70.00 to $75.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Robert W. Baird lifted their price objective on Exact Sciences from $72.00 to $88.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $74.06.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.